Document Detail

Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial.
MedLine Citation:
PMID:  14719205     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To examine the efficacy of thalidomide in the treatment of active ankylosing spondylitis (AS) refractory to conventional therapies. METHODS: In a 6-month open-label trial, we studied 13 men with different subtypes of active AS: 3 juvenile AS, 9 adult AS, and one AS with psoriasis. All patients were resistant to conventional nonbiologic therapies including nonsteroidal antiinflammatory drugs, sulfasalazine, and methotrexate. After 3 months' observation on a preexisting regimen, oral thalidomide was added, starting at 100 mg/day for 1 week, then 200 mg/day for another 23 weeks. Outcome measures included the Bath AS Disease Activity Index (BASDAI), Functional Index (BASFI), Global Index (BAS-G), IgA, C-reactive protein (CRP), and eosinophil sedimentation rate (ESR). Response to treatment was defined following the Ankylosing Spondylitis Assessment criteria. RESULTS: Three patients withdrew due to rash. Two patients were lost to followup due to lack of efficacy. Eight patients completed the trial. Four patients attained > 50% improvement (2 juvenile AS, 1 peripheral AS, and 1 psoriatic arthritis). Four patients attained > 20% improvement (2 axial and 2 peripheral AS). Total response rate accordingly was 80% (8/10). Mean BASDAI improved significantly from baseline to Week 24 (4.97 vs 3.1; p = 0.0156). Mean BASFI improved from baseline to Week 24 (5.24 vs 3.06; p = 0.0078), and BAS-G from 6.02 to 3.21 (p = 0.0078). Significant laboratory improvements were found in ESR (from 69.5 to 34.2 mm/h; p = 0.0156), but not CRP (from 6.08 to 3.01 mg/dl; p = 0.078) or IgA (from 496 to 505 mg/dl; p = 0.375). Dry mouth, constipation, and dizziness were common, but no severe adverse events were found. CONCLUSION: Thalidomide is a promising treatment for patients with active AS who are resistant to conventional therapies other than biologics.
James Cheng-Chung Wei; Tsai Wen Chan; Huey-Shyan Lin; Feng Huang; Chan-Te Chou
Related Documents :
24118835 - Vasovagal rates in flouroscopically guided interventional procedures: a study of over 8...
23754205 - Clinical evaluation of sustained-release metronidazole gel versus metronidazole solutio...
23644225 - Skup3 randomised controlled trial: polysomnographic results after uvulopalatopharyngopl...
7973475 - Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. a multic...
12832595 - An open trial of fluvoxamine for hypochondriasis.
18704475 - Hearing results of surgery for tympanosclerosis.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of rheumatology     Volume:  30     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2004-01-13     Completed Date:  2004-03-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  2627-31     Citation Subset:  IM    
Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University, Sec. 1, 110 Chien Kuo N. Road, Taichung 402, Taiwan, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / therapeutic use
Immunosuppressive Agents / therapeutic use*
Middle Aged
Severity of Illness Index
Spondylitis, Ankylosing / drug therapy*,  physiopathology
Thalidomide / therapeutic use*
Treatment Failure
Treatment Outcome
Reg. No./Substance:
0/Antirheumatic Agents; 0/Immunosuppressive Agents; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection.
Next Document:  Undifferentiated spondyloarthropathies in Brazilians: importance of HLA-B27 and the B7-CREG alleles ...